Personalizing the Treatment of Substance Use Disorders
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The focus on opioid use in previous behavioral intervention studies may leave out other important comorbid conditions that impact patient-reported outcomes and long-term recovery.
“The focus on opioid use in these previous behavioral intervention studies may, however, leave out other important co-morbid conditions that significantly impact key patient-reported outcomes related to quality of life and likelihood of meaningful long-term recovery 8.”
From Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study (2023) · cites this paper as [8]
In “Treating the Dimensions of Substance Use Disorder” (p. 114), Volkow discusses comorbid depression and insomnia, and argues that improving depression may benefit patients even without abstinence. This supports considering conditions beyond opioid use in assessing recovery, but the paper does not say that the previous behavioral intervention studies omitted those conditions or establish their effect on quality-of-life patient-reported outcomes. (LLM, conf=0.84)
Experimental — accuracy not yet measuredPsychosocial treatments for SUDs yield small to moderate benefits compared to inactive controls in the short term.
“psychosocial treatments yield small to moderate benefits compared to inactive controls in the short-term [39,40,41,42,43,44].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [42]
In “Treating the Dimensions of Substance Use Disorder” (page not specified), the paper says cognitive-behavioral treatments and contingency management have benefits for specific aspects of addiction. It does not quantify those benefits as small to moderate or compare them with inactive controls over the short term. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340 · see citing works
Self-citationVolitional social interaction prevents drug addiction in rat models
Venniro, M., Zhang, M., Caprioli, D., Hoots, J. K., Golden, S. A., Heins, C., Morales, M., Epstein, D. H., & Shaham, Y. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0246-6 · Cited by 342 · see citing works
Deep brain stimulation for treatment-resistant depression: systematic review of clinical outcomes
Morishita, T., Fayad, S. M., Higuchi, M.-A., Nestor, K. A., & Foote, K. D. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0282-1 · Cited by 216 · see citing works
Disrupted habenula function in major depression
Lawson, R. P., Nord, C. L., Seymour, B., Thomas, D. L., Dayan, P., Pilling, S., & Roiser, J. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.81 · Cited by 206 · see citing works
Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162 · see citing works
The role of the habenula in drug addiction
Velasquez, K. M., Molfese, D. L., & Salas, R. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00174 · Cited by 155 · see citing works
Friedman, A., Lax, E., Dikshtein, Y., Abraham, L., Flaumenhaft, Y., Sudai, E., Ben‐Tzion, M., Ami-Ad, L., Yaka, R., & Yadid, G. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.06.008 · Cited by 145 · see citing works
Thannickal, T. C., John, J., Shan, L., Swaab, D. F., Wu, M.-F., Ramanathan, L., McGregor, R., Chew, K., Cornford, M. E., Yamanaka, A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4953 · Cited by 138 · see citing works
Dreifuss, J. A., Griffin, M. L., Frost, K. H., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J. A., Hatch‐Maillette, M. A., Sonne, S. C., & Weiss, R. D. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.010 · Cited by 122 · see citing works
Goldstein, R. Z., Woicik, P. A., Maloney, T., Tomasi, D. G., Alia‐Klein, N., Shan, J., Honorio, J., Samaras, D., Wang, R., Telang, F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011455107 · Cited by 120 · see citing works
Self-citationOxytocin for the treatment of drug and alcohol use disorders
Lee, M. R., & Weerts, E. M. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000258 · Cited by 105 · see citing works
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
Kiluk, B. D., Carroll, K. M., Duhig, A. M., Falk, D. E., Kampman, K. M., Lai, S., Litten, R. Z., McCann, D. J., Montoya, I. D., Preston, K. L., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.004 · Cited by 61 · see citing works
Roos, C. R., Nich, C., Mun, C. J., Babuscio, T. A., Mendonca, J., Miguel, A. C., DeVito, E. E., Yip, S. W., Witkiewitz, K. A., Carroll, K. M., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107648 · Cited by 53 · see citing works
Medication development in opioid addiction: Meaningful clinical end points
Volkow, N. D., Woodcock, J., Compton, W. M., Throckmorton, D. C., Skolnick, P., Hertz, S. H., & Wargo, E. M. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan2595 · Cited by 52 · see citing works
Self-citationOutcome Measures in Medication Trials for Substance Use Disorders
McCann, D. J., Ramey, T., & Skolnick, P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0038-5 · Cited by 30 · see citing works
Dong, H., Hayashi, K., Singer, J., Milloy, M., DeBeck, K., Wood, E., & Kerr, T. H. (2019) · Addiction · doi:10.1111/add.14756 · Cited by 22 · see citing works
Stauffer, C. S., Moschetto, J. M., McKernan, S. M., Hsiang, E., Borsari, B. E., & Woolley, J. D. (2019) · Trials · doi:10.1186/s13063-019-3225-7 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., & Hall, W. D. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00346-w · Cited by 316 · see citing works
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259 · see citing works
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83 · see citing works
Amin‐Esmaeili, M., Farokhnia, M., Susukida, R., Leggio, L., Johnson, R. M., Crum, R. M., & Mojtabai, R. (2024) · Addiction · doi:10.1111/add.16409 · Cited by 43 · see citing works
Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26 · see citing works
Schuman‐Olivier, Z., Fatkin, T., Creedon, T. B., Samawi, F., Moore, S. K., Okst, K., Fredericksen, A. (., Oxnard, A. (., Roll, D., Smith, L., et al. (2023) · The American Journal on Addictions · doi:10.1111/ajad.13364 · Cited by 15 · see citing works
- Authors
- Volkow, N. D.
- Affiliations
- National Institute on Drug Abuse (US)
- Corresponding author
- Volkow, Nora D.
- ORCID
- Volkow, Nora D.
- Venue
- American Journal of Psychiatry
- Published
- 2020-02-01
- Volume
- 177
- Issue
- 2
- Pages
- 113-116
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3003347387
- Cited by
- 172
- References
- 17
- Citations by year
- 2026: 19 · 2025: 39 · 2024: 26 · 2023: 25 · 2022: 27 · 2021: 24 · 2020: 12
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- substance use disorders, personalized treatment
- MeSH terms
- Humans, Outcome Assessment, Health Care, Substance-Related Disorders, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
